Histogen Announces $4.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
November 12, 2020 08:00 ET
|
Histogen Inc
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s...
Histogen Reports Third Quarter 2020 Earnings and Provides Business Update
November 10, 2020 16:05 ET
|
Histogen Inc
Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20 Received $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage...
Histogen to Report Third Quarter 2020 Earnings on November 12, 2020
October 28, 2020 16:30 ET
|
Histogen Inc
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen and Amerimmune Enter into a Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of COVID-19
October 27, 2020 08:00 ET
|
Histogen Inc
Histogen Receives IND Approval from FDA to Initiate a Phase 1 Study of Emricasan in Mild-COVID-19 Patients to Assess Safety and Tolerability Amerimmune to Lead Development Efforts of Emricasan in a...
Histogen Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations
October 19, 2020 08:00 ET
|
Histogen Inc
SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men
October 05, 2020 08:00 ET
|
Histogen Inc
SAN DIEGO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Announces Update for its HST-002 Dermal Filler Program
September 29, 2020 08:00 ET
|
Histogen Inc
HST-002 Designated as Drug-Biologic-Device Combination Product HST-001 1b/2a Trial for Androgenic Alopecia in Men on Track for Top Line Data Results in 4Q20 HST-003 IND Submission for Regeneration...
Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee
September 16, 2020 08:00 ET
|
Histogen Inc
Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020 SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company...
Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men
September 10, 2020 08:00 ET
|
Histogen Inc
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen to Present at the HC Wainwright 22nd Annual Global Investment Conference
September 01, 2020 16:15 ET
|
Histogen Inc
SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...